On February 17, 2026, VR Adviser, LLC disclosed in a U.S. Securities and Exchange Commission filing that it sold 5,845,915 shares of Ocular Therapeutix (NASDAQ:OCUL), an estimated $71.01 million trade based on quarterly average pricing.
-
VR Adviser, LLC Sold 5,845,915 shares of Ocular Therapeutix; estimated transaction value of $70.96 million based on quarterly average price.
-
The quarter-end value of the position dropped by $65.05 million, reflecting both trading and Ocular Therapeutix share price changes.
-
The transaction represented 3.51% of VR Adviser, LLC’s reportable assets under management.
-
Following the sale, VR Adviser, LLC held 7,315,547 shares ($88.81 million)
-
Ocular Therapeutix now accounts for 4.39% of fund AUM, placing it outside the fund’s top five holdings
According to a February 17, 2026, SEC filing, VR Adviser, LLC reduced its position in Ocular Therapeutix (NASDAQ:OCUL) by 5,845,915 shares during the fourth quarter. The estimated transaction value is $70.96 million based on the average closing share price for the quarter. The quarter-end value of the position fell by $65.05 million, reflecting both the sale and changes in the stock’s price during the period.
-
VR Adviser, LLC’s sale brought its Ocular Therapeutix stake to 4.3868% of reportable AUM as of December 31, 2025
-
Top holdings after the filing:
-
NASDAQ:APGE: $641,075,869 (31.7% of AUM)
-
NASDAQ:ORKA: $125,738,853 (6.2% of AUM)
-
NASDAQ:VRDN: $120,829,904 (6.0% of AUM)
-
NASDAQ:SYRE: $120,735,276 (6.0% of AUM)
-
NASDAQ:KALV: $108,673,108 (5.4% of AUM)
-
-
As of February 17, 2026, shares of Ocular Therapeutix were priced at $6.99, down 3.98% over the past year, underperforming the S&P 500 by 15.90 percentage points.
|
Metric |
Value |
|---|---|
|
Price (as of market close February 17, 2026) |
$6.99 |
|
Market capitalization |
$1.50 billion |
|
Revenue (TTM) |
$51.95 million |
|
Net income (TTM) |
($265.94 million) |
-
Ocular Therapeutix develops and commercializes ophthalmic therapies, including marketed products such as ReSure Sealant and DEXTENZA, and is advancing a pipeline of drug delivery implants for retinal diseases, glaucoma, and dry eye.
-
The company generates revenue through product sales and strategic collaborations, leveraging its proprietary bioresorbable hydrogel technology for sustained drug delivery in ophthalmology.
-
Primary customers include ophthalmologists, eye care centers, and healthcare providers treating ocular diseases, with a focus on both U.S. and international markets through direct sales and licensing partnerships.
Ocular Therapeutix is a clinical-stage biopharmaceutical company specializing in innovative drug delivery solutions for eye diseases. The company combines proprietary hydrogel technology with established and novel therapeutics to address unmet medical needs in ophthalmology. Its strategic collaborations and diversified pipeline position it to compete in the high-growth ophthalmic pharmaceutical market.
